Rein Therapeutics, Inc.

RNTXSEC EDGAR

Pharmaceutical PreparationsCIK: 1420565

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Research and Development Expense	$4.0M	$18.0M	$17.0M	$11.2M	$4.2M
Operating Expenses	$16.3M	$27.6M	$26.6M	$20.5M	$7.3M
Operating Income (Loss)	-$16.3M	-$27.6M	-$26.6M	-$20.5M	-$7.3M
Other Nonoperating Income (Expense)	$544.0K	$318.0K	$441.0K	-$661.0K	$101.0K
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$15.7M	-$27.3M	-$27.3M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$106.0M	$22.0M	$48.5M	$16.3M	$26.5M
Assets, Current	$18.3M	$21.9M	$48.2M	$16.3M	$19.6M
Cash and Cash Equivalents, at Carrying Value	$17.3M	$5.2M	$3.6M	$7.0M	$5.3M
Liabilities	$7.7M	$3.4M	$4.6M	$4.2M	$10.4M
Liabilities, Current	$4.4M	$3.4M	$4.5M	$4.0M	$5.8M
Accounts Payable, Current	$1.2M	$1.7M	$1.2M	$1.6M	$1.5M
Stockholders' Equity Attributable to Parent	$18.6M	$18.6M	$12.2M	$16.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$19.8M	-$24.9M	-$23.8M	-$20.5M	-$26.5M
Net Cash Provided by (Used in) Investing Activities	$16.2M	$26.5M	-$35.9M	$6.4M	-$2.8M
Net Cash Provided by (Used in) Financing Activities	$15.8M	$15.8M	$55.7M	$15.8M	$24.0M
Payments to Acquire Property, Plant, and Equipment	—	—	$157.0K	$5.0K	$151.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)